The global CAR T-Cell Therapy market is estimated to develop at a compound annual growth rate (CAGR) of 31.2%.
The global CAR T-Cell Therapy market is estimated to develop at a compound annual growth rate (CAGR) of 31.2%. The global CAR T-Cell Therapy market size was valued at USD 6.1 billion in 2021, and it is predicted to exceed USD 21.0 billion by 2030. The study investigates several elements and their consequences on the growth of the CAR T-Cell Therapy market.
Full Report is Ready | Request Sample of This Report @ https://www.novaoneadvisor.com/report/sample/6000
CAR T-cell therapy is a recently approved treatment option for various types of cancer. CAR T cell therapy is provided by removing or harvesting T cells from a patient with cancer, transfecting the cells with CAR genes that are directed against the patient’s tumor type, expanding the modified T cell population, and reinfusing the cells back into the patient. Currently, Kymriah, Yescarta, Tecartus, Breyanzi, and ABECMA are the CAR T-cell therapy approved products for acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others.
The global CAR T-cell therapy market is driven by increase in incidence of cancer and strong product pipeline. North America dominated the global CAR T-cell therapy market in 2020 and the trend is anticipated to continue during the forecast period. Highly structured healthcare industry, early adoption of new products, high prevalence rate of cancer, and presence of major players are expected to propel the CAR T-cell therapy market in North America. Asia Pacific is likely to be a highly lucrative market for CAR T-cell therapy during the forecast period. The market in the region is projected to expand at a high CAGR from 2022 to 2030.
Report Scope of the CAR T-cell Therapy Market
| Report Coverage | Details |
| Market Size | US$ 21.0 Billion by 2030 |
| Growth Rate | CAGR of 31.2% from 2022 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
Increase in Incidence of Cancer and Strong Product Pipeline to Drive Global Market
Increase in incidence of cancer and strong product pipeline are anticipated to boost the growth of the global CAR T-cell therapy market. According to the WHO, one in five people develop cancer during their lifetime, and one in eight men and one in 11 women die from the disease. These new estimates suggest that more than 50 million people are living within five years of a past cancer diagnosis. According to the WHO, in 2020, around 544,352 new cases of non-Hodgkin lymphoma were recorded globally.
Strong product pipeline is a major factor driving the demand for CAR T-cell therapy products. For instance, Autolus Therapeutics plc has one innovative product, AUTO1, in phase I trial for treatment of adult acute lymphoblastic leukemia. AUTO1 contains obecabtageneautoleucel, which is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.
Full Report is Ready |Quick Buy This Premium Report From Here: https://www.novaoneadvisor.com/report/checkout/6000
AxicabtageneCiloleucel to Dominate CAR T-cell Therapy Market
In terms of product type, the global CAR T-cell therapy market has been classified into axicabtageneciloleucel, tisagenlecleucel, brexucabtageneautoleucel, lisocabtagenemaraleucel, idecabtagenevicleucel, and others. The axicabtageneciloleucel segment dominated the global CAR T-cell therapy market in 2020 and the trend is expected to continue during the forecast period. Yescarta is a product, which contains axicabtageneciloleucel. Increase in demand for Yescarta in the treatment of diffuse large B-cell lymphoma and follicular lymphoma is likely to boost the growth of the segment during the forecast period. In October 2017, Kite Pharma, Inc. received the U.S. FDA approval for Yescarta for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Tisagenlecleucel was the second largest segment in terms of market share in 2020. Increase in demand for Kymriah for treatment of acute lymphoblastic lymphoma and product approval in different countries are likely to drive the segment.
Diffuse Large B-cell Lymphoma to be Highly Lucrative
Based on indication, the global CAR T-cell therapy market has been categorized into acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others. The diffuse large B-cell lymphoma segment dominated the CAR T-cell therapy market due to increase in incidence of diffuse large B-cell lymphoma. Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Increase in number of cases of non-Hodgkin lymphoma is likely to propel the segment during the forecast period. According to WHO, globally, around 544,352 new non-Hodgkin lymphoma cases were recorded in 2020.
Hospitals to Emerge as Significant End-user
In terms of end-user, the global CAR T-cell therapy market has been divided into hospitals and cancer treatment centers. The hospitals segment led the global CAR T-cell therapy market in terms of revenue in 2020 and the trend is projected to continue during the forecast period. The hospitalization for cancer treatment is anticipated to boost the growth of the hospitals segment. Moreover, increase in use of CAR T-Cell therapy in the treatment of cancers contributes to the segment’s large market share. The segment is driven by surge in number of cancer patients who visit hospital for treatment of cancer.
North America to Dominate CAR T-cell Therapy Market
In terms of region, the global CAR T-cell therapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global CAR T-cell therapy market in 2020, followed by Europe. North America’s large market share can be ascribed to technologically advanced research and treatment platforms, increase in number of cancer patients, new product launches, and presence of major players. The CAR T-cell therapy market in Asia Pacific is anticipated to expand at a high CAGR from 2022 to 2030. This can be ascribed to the presence of developing countries with commercial hubs, expansion of business organizations, rise in awareness about CAR T-cell therapy, improvement in healthcare infrastructure, and increase in investments by companies..
Some of the prominent players in the CAR T-Cell Therapy market include:
Pfizer, Inc., Novartis AG, Bristol-Myers Squibb, Amgen, Inc., Sorrento Therapeutics, Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Merck & Co., Inc., and bluebird bio, Inc.
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
Global CAR T-cell Therapy Market: Segmentation
- CAR T-cell Therapy Market, by Product Type
- AxicabtageneCiloleucel
- Tisagenlecleucel
- BrexucabtageneAutoleucel
- LisocabtageneMaraleucel
- IdecabtageneVicleucel
- Others
- CAR T-cell Therapy Market, by Indication
- Acute Lymphocytic Leukemia
- Diffuse Large B-cell lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Multiple Myeloma
- Others
- CAR T-cell Therapy Market, by End-user
- Hospitals
- Cancer Treatment Centers
Regional Segmentation
- Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]
- Europe [Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
- North America [United States, Canada, Mexico]
- South America [Brazil, Argentina, Columbia, Chile, Peru]
- Middle East & Africa [GCC, North Africa, South Africa]
Click Here to View Full Report Table of Contents
Key Questions Answered in CAR T-Cell Therapy Market Report
What will be the sales/revenue generated by CAR T-Cell Therapy across all regions during the forecast period?
What are the opportunities in the global CAR T-Cell Therapy market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which application is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
What is the market position of different companies operating in the global market?
Full Report is Ready |Quick Buy This Premium Report From Here: https://www.novaoneadvisor.com/report/checkout/6000
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333
About Us
Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.
We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. We endeavor to give our clients latest insights on upcoming technologies, new developing markets, dynamically changing business conditions and most recent business-driven applications. These insights help our clients to take informed decisions for their business growth. We for the most part center around supporting our clients with aggressive insight, helping them to anchor an upper hand in the market and achieve reasonable development in various market spaces. Capable with an exceedingly skilled, experienced and to a great degree qualified group of specialists including SMEs, investigators and advisors, we attempt to provide value-added business solutions to our customers. Through dedicated subjective and quantitative market research techniques and supporting consulting assignments, we adeptly formulate competitive strategies to address business challenges for our customers through investigating market drifts, trends and rising advances in emerging technologies.
For Latest Update Follow Us:
https://www.linkedin.com/company/nova-one-advisor
https://twitter.com/NovaOneAdvisor
https://www.facebook.com/Nova-One-Advisor-116142276949837/